Jump to main content
Jump to site search

Issue 8, 2017
Previous Article Next Article

Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

Author affiliations

Abstract

A phospholipid-mimic oxaliplatin prodrug (Oxalipid) was synthesized, which could self-assemble into a liposomal nanostructure with a drug loading ratio as high as 27 wt%. Compared to free oxaliplatin, the resulting Oxalipid liposome displayed elongated blood circulation, increased tumor accumulation and improved anticancer efficacy against the metastatic triple negative breast cancer (TNBC).

Graphical abstract: Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 19 Jan 2017, accepted on 31 Mar 2017 and first published on 31 Mar 2017


Article type: Communication
DOI: 10.1039/C7BM00058H
Citation: Biomater. Sci., 2017,5, 1522-1525
  •   Request permissions

    Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

    B. Feng, F. Zhou, W. Lu, D. Wang, T. Wang, C. Luo, H. Wang, Y. Li and H. Yu, Biomater. Sci., 2017, 5, 1522
    DOI: 10.1039/C7BM00058H

Search articles by author

Spotlight

Advertisements